Serdolect: Uses, Dosage & Side Effects
An atypical antipsychotic used to treat schizophrenia in adults when other antipsychotics have been inadequate
Serdolect (sertindole) is an atypical antipsychotic medication used to treat schizophrenia in adults who have not responded adequately to at least one other antipsychotic drug. Developed by H. Lundbeck A/S, sertindole acts on dopamine D2 and serotonin 5-HT2A receptors in the brain, helping to correct the chemical imbalances that cause psychotic symptoms. Serdolect is approved in the European Economic Area but requires careful cardiac monitoring due to its potential to prolong the QT interval on ECG. It is available only by prescription and is reserved as a second-line treatment option.
Quick Facts: Serdolect
Key Takeaways
- Serdolect (sertindole) is an atypical antipsychotic approved for treating schizophrenia only when at least one other antipsychotic has been tried and found ineffective or not tolerated.
- Mandatory ECG monitoring is required before treatment, at 3 weeks or when reaching 16 mg daily, every 3 months during maintenance, and before and after any dose change – because sertindole can prolong the QT interval.
- Serdolect must not be used in patients with uncorrected low potassium or magnesium, known QT prolongation, significant cardiovascular disease, severe liver impairment, or concurrently with other QT-prolonging drugs.
- Common side effects include nasal congestion, ejaculatory dysfunction, dizziness, dry mouth, and weight gain; most are manageable but cardiac effects require ongoing medical supervision.
- Treatment should not be stopped abruptly – gradual dose reduction under medical supervision is necessary to avoid withdrawal symptoms and relapse of the underlying condition.
What Is Serdolect and What Is It Used For?
Serdolect contains the active substance sertindole, which belongs to a class of medications known as atypical (or second-generation) antipsychotics. These drugs represent an advancement over first-generation antipsychotics because they generally carry a lower risk of extrapyramidal side effects – involuntary movement disorders that were a significant limitation of older antipsychotic medications. Sertindole was developed by the Danish pharmaceutical company H. Lundbeck A/S and was first approved in Europe in 1996, though it was temporarily suspended from 1998 to 2002 due to cardiac safety concerns before being reintroduced with enhanced monitoring requirements.
The mechanism of action of sertindole involves selective blockade of multiple neurotransmitter receptors in the brain. It primarily antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, with additional affinity for alpha-1 adrenergic receptors. The dual dopamine-serotonin blockade is characteristic of atypical antipsychotics and is thought to contribute to efficacy against both the positive symptoms of schizophrenia (such as hallucinations, delusions, and thought disorder) and the negative symptoms (such as social withdrawal, emotional flattening, and reduced motivation). Sertindole demonstrates preferential activity in the limbic system of the brain rather than the striatum, which is believed to account for its lower propensity to cause extrapyramidal symptoms compared to typical antipsychotics.
Serdolect is specifically indicated for the treatment of schizophrenia in adult patients. However, it is not a first-line treatment. Current regulatory approvals restrict its use to patients who have not responded adequately to at least one other antipsychotic medication, or who cannot tolerate other antipsychotics due to unacceptable side effects. This restricted indication reflects the drug's unique risk-benefit profile: while sertindole demonstrates good efficacy and a favorable neurological side-effect profile, it carries a specific cardiac risk (QT interval prolongation) that necessitates careful patient selection and ongoing monitoring.
Schizophrenia is a chronic and often severe mental health condition affecting approximately 1% of the global population. It typically presents in late adolescence or early adulthood and is characterized by disturbances in thinking, perception, emotions, and behavior. The condition requires long-term treatment, and many patients need to try multiple medications before finding one that adequately controls their symptoms with acceptable side effects. For these patients, sertindole provides an important alternative treatment option with a distinctive pharmacological profile.
Pharmacokinetically, sertindole is well absorbed after oral administration and extensively metabolized in the liver, primarily through the cytochrome P450 enzymes CYP2D6 and CYP3A4. It has a notably long elimination half-life of approximately 3 days (72 hours), which allows for convenient once-daily dosing. Steady-state plasma concentrations are typically achieved after 2 to 3 weeks of consistent dosing. The drug's long half-life also means that dose adjustments take time to reach full effect, and the medication persists in the body for an extended period after the last dose.
Serdolect is not a first-choice antipsychotic. It should only be prescribed for patients with schizophrenia who have not responded adequately to, or who cannot tolerate, at least one other antipsychotic medication. This restriction is due to the mandatory cardiac monitoring requirements associated with its use. Your prescribing doctor will have considered other treatment options before recommending Serdolect.
What Should You Know Before Taking Serdolect?
Contraindications
There are several absolute contraindications for Serdolect. The medication must not be used if any of the following conditions apply:
- Allergy to sertindole: Do not use Serdolect if you are allergic to sertindole or any of the other ingredients in the tablet (see the Ingredients section below).
- Low potassium or magnesium: Uncorrected hypokalemia (low potassium) or hypomagnesemia (low magnesium) in the blood. These electrolyte disturbances increase the risk of dangerous cardiac arrhythmias.
- Cardiovascular disease: Clinically significant cardiovascular disease, including heart failure with fluid retention (edema), cardiomegaly (enlarged heart), irregular or slow heart rate (bradycardia), or any arrhythmia.
- QT prolongation: Congenital long QT syndrome, a history of acquired QT prolongation on ECG, or a family history of congenital long QT syndrome.
- Severe liver impairment: Serdolect is extensively metabolized by the liver, and severe hepatic impairment leads to unpredictable drug accumulation.
- Concurrent QT-prolonging drugs: Drugs known to prolong the QT interval, including certain antiarrhythmics, antipsychotics, antibiotics, and antihistamines (see Drug Interactions section).
- Concurrent strong CYP enzyme inhibitors: Drugs that significantly inhibit hepatic metabolism, including ketoconazole, itraconazole, erythromycin, clarithromycin, HIV protease inhibitors, and certain calcium channel blockers.
Warnings and Precautions
Serdolect can prolong the QT interval on the electrocardiogram (ECG), which may in rare cases lead to life-threatening ventricular arrhythmias, including Torsades de Pointes. ECG monitoring is mandatory before starting treatment and at regular intervals throughout therapy. If the QTc interval exceeds 500 milliseconds, Serdolect must be discontinued immediately.
Speak to your doctor before taking Serdolect if any of the following conditions or situations apply to you:
- Vomiting or diarrhea: These conditions can lead to electrolyte disturbances (particularly low potassium), which increase the risk of cardiac arrhythmias. Your doctor may need to check your blood potassium levels.
- Impaired liver function: Mild to moderate liver problems may require slower dose escalation, more frequent monitoring, and potentially a lower maintenance dose.
- Parkinson’s disease: Antipsychotics can worsen Parkinsonian symptoms by blocking dopamine receptors.
- Diabetes or risk factors for diabetes: Atypical antipsychotics have been associated with metabolic changes including hyperglycemia (raised blood sugar) and the development or worsening of diabetes mellitus. Blood glucose monitoring may be necessary.
- Risk factors for stroke: Including high blood pressure, history of stroke or transient ischemic attack, heart disease, diabetes, high cholesterol, dementia, or smoking. Atypical antipsychotics have been associated with an increased risk of cerebrovascular events in elderly patients with dementia.
- Age over 65 years: Elderly patients may require slower dose titration and lower maintenance doses. There is also a small increased risk of mortality in elderly patients with dementia treated with antipsychotics.
- History of blood clots (venous thromboembolism): Antipsychotic medications have been associated with the formation of venous blood clots, including deep vein thrombosis and pulmonary embolism.
- History of seizures: Antipsychotics may lower the seizure threshold.
- Tardive dyskinesia: Uncontrollable movements, particularly of the mouth and tongue, may develop during antipsychotic treatment. If these occur, contact your doctor immediately.
Seek immediate medical attention if you develop a combination of high fever, unusual muscle stiffness, altered consciousness, sweating, and rapid heartbeat. These may be signs of neuroleptic malignant syndrome, a rare but potentially life-threatening reaction to antipsychotic medications that requires emergency treatment.
Required Monitoring
Before and during treatment with Serdolect, your doctor will perform several important tests and examinations:
- ECG (electrocardiogram): Mandatory before starting treatment. Repeated when you reach a daily dose of 16 mg or after 3 weeks of treatment (whichever comes first). During maintenance treatment, an ECG should be performed every 3 months. Additional ECGs are required before and after any dose increase, and whenever any medication changes could affect sertindole blood levels.
- Blood tests for electrolytes: Potassium and magnesium levels must be checked before starting treatment. If levels are too low, they must be corrected before Serdolect can be initiated. Ongoing monitoring is necessary, particularly if you develop vomiting, diarrhea, or start taking diuretic medications.
- Blood pressure monitoring: Serdolect can cause orthostatic hypotension (a drop in blood pressure when standing), particularly at the start of treatment. This is minimized by the gradual dose titration schedule.
Pregnancy and Breastfeeding
Serdolect is not recommended during pregnancy. While animal studies have not shown direct harmful effects on fertility or fetal development, there are insufficient data from use in pregnant women. Neonates exposed to antipsychotics during the third trimester of pregnancy may experience withdrawal symptoms after birth, including tremors, muscle stiffness or weakness, drowsiness, agitation, breathing difficulties, and feeding problems. If you become pregnant while taking Serdolect, or are planning to become pregnant, contact your doctor immediately to discuss the risks and benefits of continued treatment.
Serdolect should not be used during breastfeeding unless your doctor considers it absolutely necessary. The active substance sertindole passes into breast milk, and the effects on the nursing infant are not fully known. If treatment with Serdolect is considered essential, your doctor may recommend discontinuing breastfeeding.
Serdolect may have side effects that can affect sexual function and the ability to conceive. These effects are typically reversible upon discontinuation. Discuss any concerns about sexual function or fertility with your doctor.
Driving and Operating Machinery
While sertindole is not typically associated with sedation or drowsiness at the same rate as some other antipsychotics, it can cause dizziness, particularly when standing up quickly (orthostatic hypotension), especially at the start of treatment. Do not drive or operate machinery until you know how Serdolect affects you personally. You are responsible for assessing your own fitness to drive or perform tasks that require alertness. If you experience any symptoms that could impair your concentration or coordination, refrain from these activities and discuss with your doctor.
Important Information About Ingredients
Lactose: Serdolect tablets contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medication.
Sodium: This medicine contains less than 1 mmol (23 mg) sodium per tablet, meaning it is essentially sodium-free.
How Does Serdolect Interact with Other Drugs?
Drug interactions with Serdolect are of particular clinical importance because of the medication's effect on cardiac conduction (QT interval prolongation) and its metabolism through hepatic cytochrome P450 enzymes. Some interactions are absolutely contraindicated (must never be combined), while others require careful monitoring. Always inform your doctor, pharmacist, or nurse about all prescription and over-the-counter medications, vitamins, herbal remedies, and dietary supplements you are taking.
Contraindicated Combinations (Must Not Be Used Together)
| Drug / Drug Class | Reason | Examples |
|---|---|---|
| QT-prolonging antiarrhythmics | Additive QT prolongation; risk of life-threatening Torsades de Pointes | Quinidine, amiodarone, sotalol, dofetilide |
| QT-prolonging antipsychotics | Additive QT prolongation risk | Thioridazine |
| Macrolide antibiotics | QT prolongation and inhibition of sertindole metabolism (CYP3A4) | Erythromycin, clarithromycin |
| Fluoroquinolone antibiotics | Additive QT prolongation | Gatifloxacin, moxifloxacin |
| Antihistamines (older generation) | QT prolongation risk | Terfenadine, astemizole |
| Azole antifungals (oral) | Strong CYP3A4 inhibition; significantly increased sertindole blood levels | Ketoconazole, itraconazole |
| HIV protease inhibitors | Strong CYP3A4 inhibition | Indinavir, ritonavir |
| Calcium channel blockers (certain) | CYP3A4 inhibition; increased sertindole levels | Diltiazem, verapamil |
| Cisapride | QT prolongation | Cisapride (gastrointestinal medication) |
| Lithium | Combined cardiac and neurological risks | Lithium (mood stabilizer) |
| Cimetidine | Inhibition of sertindole metabolism | Cimetidine (antacid) |
Important Interactions Requiring Caution
| Drug / Drug Class | Effect | Clinical Advice |
|---|---|---|
| Fluoxetine, Paroxetine | CYP2D6 inhibitors; may increase sertindole blood levels by 2–3 fold | May require Serdolect dose reduction and additional ECG monitoring. Inform your doctor if starting or stopping these antidepressants. |
| Rifampicin | Potent CYP3A4 inducer; may significantly reduce sertindole blood levels | May reduce the effectiveness of Serdolect. Your doctor may need to adjust the dose and perform additional monitoring. |
| Carbamazepine, Phenytoin, Phenobarbital | CYP enzyme inducers; may reduce sertindole blood levels | These anticonvulsants can decrease the effectiveness of Serdolect. Dose adjustment and monitoring are necessary. |
| Dopamine agonists | Pharmacological antagonism; sertindole may counteract the effects of dopamine agonists and vice versa | Relevant for patients with concurrent Parkinson's disease. This combination requires careful clinical assessment. |
| Diuretics (water tablets) | Can reduce potassium levels, increasing cardiac arrhythmia risk with Serdolect | Regular monitoring of blood potassium levels is essential. Potassium supplementation may be necessary. |
You should avoid alcohol while taking Serdolect. Although alcohol is not expected to have a direct pharmacological interaction with sertindole, both substances can affect the central nervous system and cardiovascular system. Alcohol may worsen side effects such as dizziness, lightheadedness, and orthostatic hypotension, and may impair judgment and coordination.
What Is the Correct Dosage of Serdolect?
Always take Serdolect exactly as your doctor or pharmacist has instructed. The dose must be carefully increased (titrated) over several weeks to minimize the risk of side effects, particularly orthostatic hypotension (dizziness when standing). The slow titration schedule also allows your doctor to monitor for cardiac effects at each dose level. Do not change your dose without consulting your doctor.
Adults
Starting Dose
4 mg once daily. This low starting dose is essential for safety and tolerability.
Dose Titration
The dose is increased by 4 mg increments every 4–5 days. The typical titration schedule is: 4 mg → 8 mg → 12 mg → 16 mg (with ECG at 16 mg or after 3 weeks). Further increases to 20 mg or 24 mg may be considered if clinically necessary.
Maintenance Dose
12–20 mg once daily. This is the usual effective dose range for most patients.
Maximum Dose
24 mg once daily. This maximum dose should only be considered in exceptional circumstances and requires careful ECG monitoring.
Children and Adolescents
Serdolect should not be used in children and adolescents (under 18 years of age) as there is no data available on safety and efficacy in this age group.
Elderly Patients (Over 65 Years)
Elderly patients may require a slower dose titration period than is normally recommended. Your doctor will likely increase the dose more gradually and may prescribe a lower maintenance dose. Elderly patients with dementia-related psychosis treated with antipsychotic medications are at increased risk of death and cerebrovascular adverse events. Serdolect has not been studied specifically in elderly patients with dementia and is not approved for this use.
Patients with Liver Impairment
If you have mild to moderate liver problems, your doctor will want to monitor you more closely and will likely increase your dose of Serdolect more slowly than normally recommended. A lower maintenance dose may also be prescribed. Serdolect must not be used in patients with severe liver impairment.
Patients with Kidney Impairment
Serdolect can be used at normal doses in patients with impaired kidney function, as the kidneys play a minor role in the elimination of sertindole.
How to Take Serdolect
Swallow the tablet whole with a glass of water, at the same time each day. Serdolect can be taken with or without food. Maintaining a consistent daily dosing time helps maintain stable drug levels in the blood and supports adherence to the treatment regimen.
Missed Dose
Do not take a double dose to make up for a forgotten dose. If you miss your daily dose of Serdolect, contact your doctor. Due to the medication's specific dosing requirements and the need for ECG monitoring, your doctor will help you resume your treatment in the correct and safe manner. If you have missed several consecutive doses, your doctor may need to restart the titration schedule from a lower dose.
Overdose
If you suspect an overdose with Serdolect, contact your local emergency services or go to the nearest emergency department immediately, even if you do not feel unwell.
Symptoms of sertindole overdose may include increased drowsiness, slurred speech, increased heart rate (tachycardia), and low blood pressure (hypotension). QT prolongation may also occur, which can lead to dangerous cardiac arrhythmias. Treatment of overdose is supportive and symptomatic, with particular attention to cardiac monitoring, maintaining adequate blood pressure, and ensuring an open airway. There is no specific antidote for sertindole.
Stopping Treatment
Do not stop taking Serdolect without consulting your doctor, even if you feel better. Schizophrenia is a long-term condition, and the underlying illness may persist even when symptoms are controlled. Stopping treatment prematurely can cause your symptoms to return, and you may also experience involuntary movements. Abrupt discontinuation of Serdolect can cause withdrawal symptoms, including nausea, vomiting, sweating, and difficulty sleeping (insomnia). Your doctor will determine when and how to discontinue your treatment, typically by gradually reducing the dose.
What Are the Side Effects of Serdolect?
Like all medicines, Serdolect can cause side effects, although not everyone experiences them. Some side effects are common and generally manageable, while others are rare but potentially serious. The following classification is based on clinical trial data and post-marketing surveillance reports. Understanding the frequency and nature of these effects helps you and your doctor make informed decisions about your treatment.
Contact your doctor immediately or go to the nearest emergency department if you experience: very fast, irregular, or forceful heartbeat, dizziness or fainting, difficulty breathing or chest pain (possible life-threatening heart rhythm disturbance); high fever combined with rapid breathing, sweating, muscle stiffness, and drowsiness (possible neuroleptic malignant syndrome); or blood clot symptoms such as swelling, pain, and redness in the legs or chest pain with breathing difficulties.
Very Common
- Rhinitis (nasal congestion): Inflammation of the nasal passages causing sneezing, itching, runny nose, and nasal stuffiness; related to alpha-1 adrenergic receptor blockade
- Absent ejaculation: Complete inability to ejaculate during orgasm; a recognized effect of serotonin and alpha-1 adrenergic receptor blockade, typically reversible upon dose reduction or discontinuation
Common
- Dizziness or postural hypotension: Lightheadedness when standing up due to a drop in blood pressure; most common during dose titration and usually improves over time
- Dry mouth: Reduced saliva production
- Weight gain: Metabolic side effect common to many atypical antipsychotics
- Shortness of breath (dyspnea): Mild breathing difficulty
- Peripheral edema: Swelling of hands and feet due to fluid retention
- Paresthesia: Unusual tingling or crawling sensations in the skin
- Decreased ejaculation volume: Reduced volume of ejaculate
- Erectile dysfunction: Difficulty achieving or maintaining an erection
- QT prolongation: Changes in the heart's electrical activity detectable on ECG; may cause symptoms such as palpitations and fainting
- Urinary abnormalities: Red and white blood cells in the urine
Uncommon
- Torsades de Pointes: A specific type of irregular heart rhythm that can be life-threatening; this is the most serious cardiac concern with sertindole
- Hyperglycemia: Elevated blood sugar levels; may indicate the onset of or worsening of diabetes
- Hyperprolactinemia: Increased blood levels of the hormone prolactin, which may cause breast enlargement, breast tenderness, or spontaneous milk production (galactorrhea)
- Seizures: Convulsions or fits; more common in patients with a pre-existing seizure disorder
- Syncope: Fainting episodes
- Tardive dyskinesia: Uncontrollable movements, mainly of the mouth, tongue, and limbs; a recognized complication of prolonged antipsychotic use that may be irreversible
Rare
- Neuroleptic malignant syndrome (NMS): A combination of high fever, rapid breathing, sweating, muscle stiffness, and drowsiness or altered consciousness; a medical emergency requiring immediate hospitalization
Frequency Not Known
- Venous thromboembolism (VTE): Blood clots in the veins, particularly in the legs (deep vein thrombosis), which can travel to the lungs causing pulmonary embolism – symptoms include leg swelling, pain, and redness, or chest pain and breathing difficulty
A small increase in the number of deaths has been reported in elderly patients with dementia treated with antipsychotic medications. Serdolect is not approved for the treatment of dementia-related behavioral disturbances.
Many side effects of sertindole are dose-dependent and may improve with dose adjustment. Sexual side effects (ejaculatory dysfunction, erectile dysfunction) are among the most commonly reported and can significantly affect quality of life. These effects are typically reversible when the dose is reduced or the medication is discontinued. If you experience any side effects that trouble you, discuss them openly with your doctor, as alternative treatments or management strategies may be available.
If you experience any adverse effects while taking Serdolect, even if they are not listed here, you can report them directly to your national pharmacovigilance authority (e.g., the MHRA Yellow Card scheme in the UK, the EMA EudraVigilance system in Europe). Reporting helps monitor the ongoing safety of medicines.
How Should You Store Serdolect?
Proper storage of Serdolect is important to ensure the medication remains effective and safe throughout its use. Follow these guidelines:
- Storage conditions: Store in the original packaging to protect from light. No special temperature storage requirements are listed, but storing at room temperature (below 25°C / 77°F) is generally recommended.
- Keep out of reach of children: Store all medicines securely where children cannot see or reach them.
- Expiry date: Do not use Serdolect after the expiry date stated on the label or carton. The expiry date refers to the last day of the stated month.
- Disposal: Do not dispose of medications via household waste or down drains. Return unused or expired Serdolect to your local pharmacy for safe disposal. These measures help protect the environment.
What Does Serdolect Contain?
The active pharmaceutical ingredient in Serdolect is sertindole. The tablets are available in two strengths:
- Serdolect 4 mg: Each film-coated tablet contains 4 mg of sertindole. The tablets are oval, rounded on the upper and lower surfaces, yellow in color, and marked with “S4” on one side.
- Serdolect 12 mg: Each film-coated tablet contains 12 mg of sertindole. The tablets are oval, rounded on the upper and lower surfaces, beige in color, and marked with “S12” on one side.
Inactive Ingredients (Excipients)
The inactive ingredients in Serdolect tablets serve various pharmaceutical functions including binding, filling, coating, and coloring:
- Tablet core: Cornstarch, lactose monohydrate, hydroxypropylcellulose, hypromellose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate.
- Film coating: Macrogol 400, titanium dioxide, iron oxide (E172). The 4 mg tablet contains yellow iron oxide, while the 12 mg tablet contains both yellow and red iron oxide.
Serdolect is available in pack sizes of 7, 10, 14, 20, 28, 30, 50, 98, or 100 tablets. Not all pack sizes may be marketed in every country. Serdolect is manufactured by H. Lundbeck A/S, Denmark, and is approved across the European Economic Area.
Serdolect tablets contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to certain sugars, consult your doctor before taking this medicine.
Frequently Asked Questions About Serdolect
Serdolect (sertindole) is an atypical antipsychotic used to treat schizophrenia in adults. It is specifically reserved for patients who have not responded adequately to, or who cannot tolerate, at least one other antipsychotic medication. Schizophrenia is a chronic mental health condition characterized by hallucinations, delusions, disordered thinking, social withdrawal, and emotional flattening. Serdolect works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain to help correct the chemical imbalances underlying these symptoms.
Serdolect can prolong the QT interval on the electrocardiogram (ECG), which is a measure of the time it takes for the heart's electrical system to recharge between beats. A prolonged QT interval increases the risk of a potentially life-threatening abnormal heart rhythm called Torsades de Pointes. For this reason, an ECG is mandatory before starting treatment, after reaching a 16 mg daily dose or after 3 weeks, every 3 months during maintenance treatment, and before and after any dose change. If the QTc interval exceeds 500 milliseconds at any time, Serdolect must be stopped immediately.
No, you should never stop taking Serdolect without consulting your doctor, even if you feel well. Schizophrenia is a chronic condition and symptoms may return if treatment is stopped prematurely. Abrupt discontinuation can also cause withdrawal symptoms including nausea, vomiting, sweating, and insomnia, as well as involuntary movements. When it is time to stop treatment, your doctor will guide you through a gradual dose reduction to minimize these risks.
Dizziness when standing up (orthostatic hypotension) is a common side effect, especially at the start of treatment. This is caused by a drop in blood pressure and is why Serdolect is started at a low dose and increased gradually. To minimize this effect, rise slowly from sitting or lying positions, especially in the morning or after prolonged sitting. Avoid standing still for long periods, and stay well hydrated. This side effect typically improves as your body adjusts to the medication. If dizziness is severe or persistent, contact your doctor.
Weight gain is a common side effect of many atypical antipsychotics, including Serdolect. The degree of weight gain varies between individuals and may be influenced by genetic factors, diet, physical activity, and the specific antipsychotic used. Clinical studies suggest that sertindole may cause less weight gain than some other atypical antipsychotics (such as olanzapine or clozapine), but more than others. A healthy diet and regular physical activity can help manage this side effect. Discuss any significant weight changes with your doctor, as they may also want to monitor your blood sugar and cholesterol levels.
Serdolect is primarily available in European countries. It is approved across the European Economic Area (EEA) under the name Serdolect in countries including Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Iceland, Latvia, Netherlands, Norway, Poland, Romania, Slovakia, Spain, and Sweden. It is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States. Availability may vary by country, and the specific regulatory status should be verified with your local health authority or pharmacist.
References
This article is based on current international medical guidelines, regulatory documents, and peer-reviewed research. All sources meet evidence level 1A standards.
- European Medicines Agency (EMA). Serdolect (sertindole) – Summary of Product Characteristics. EMA/CHMP; 2024. Comprehensive regulatory document covering indications, dosing, contraindications, drug interactions, and safety data for sertindole.
- National Institute for Health and Care Excellence (NICE). Psychosis and Schizophrenia in Adults: Prevention and Management (CG178). NICE; 2024. Evidence-based guideline for the treatment of schizophrenia, including recommendations for antipsychotic selection and monitoring.
- Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. 14th ed. Wiley-Blackwell; 2024. Comprehensive prescribing reference for psychiatric medications including sertindole, with guidance on ECG monitoring and drug interactions.
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3
- Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21(11):911-936. doi:10.2165/00023210-200721110-00004
- Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341-356. doi:10.1002/wps.20567
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. International framework for essential medicines and treatment guidelines for mental health conditions.
- Kasper S, Hale A, Azorin JM, Möller HJ. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1999;249(Suppl 2):S1-S14. doi:10.1007/PL00014180
- Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge University Press; 2021. Authoritative reference on the pharmacology and clinical use of antipsychotic medications.
- Sertindole Safety Review Committee. Report on the benefit-risk balance of sertindole. European Medicines Agency; 2002. Review document supporting the reintroduction of sertindole with enhanced cardiac monitoring requirements.
Editorial Team
This article has been written and reviewed by the iMedic medical editorial team according to our strict editorial standards. Our team consists of licensed physicians, pharmacists, and medical researchers with expertise in psychiatry and clinical pharmacology.
Content developed by iMedic's medical writing team based on current international guidelines (EMA SmPC, NICE, Maudsley Guidelines) and peer-reviewed psychopharmacological research.
Independently reviewed and fact-checked by the iMedic Medical Review Board, comprising board-certified specialists in psychiatry and clinical pharmacology.
All medical claims are supported by Level 1A evidence (systematic reviews, meta-analyses, and randomized controlled trials) following the GRADE evidence framework.
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent with no conflicts of interest.